Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Multiple Sclerosis: Myeloperoxidase Immunoradiology Improves Detection of Acute and Chronic Disease in Experimental Model.
Natalizumab to fingolimod washout in patients at risk of PML: When good intentions yield bad outcomes.
FDA approves first oral drug to reduce MS relapses
Intramuscular interferon beta-1a is effective in Japanese patients with relapsing-remitting multiple sclerosis: a pre-treatment versus treatment comparison study of gadolinium-enhanced MRI brain lesions.
Genetics of primary progressive multiple sclerosis.
The Ambivalent Role of Apoptosis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis.
Abstracts of ECTRIMS (Congress of the European Committee for Treatment and Research in Multiple Sclerosis) 2013. October 2-5, 2013. Copenhagen, Denmark.
ICV-transplanted human glial precursor cells are short-lived yet exert immunomodulatory effects in mice with EAE.
No excess of mitochondrial DNA deletions within muscle in progressive multiple sclerosis.
Corticosteroids provoke acute endothelial injury - an ideal ground for thrombosis in multiple sclerosis.
The spectrum of MOG autoantibody-associated demyelinating diseases.
[Sexuality of men with neurologic disorders].
Impact of diagnosis and early treatment on the course of multiple sclerosis.
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis.
Parallel states of pathological Wnt signaling in neonatal brain injury and colon cancer.
Neurologic complications in patients with inflammatory bowel disease: Increasing relevance in the era of biologics.
Evaluation of olfactory dysfunction in neurodegenerative diseases.
Disease Suppression Persists With Ozanimod at 72 Weeks in MS
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.
Laquinimod, a Quinoline-3-Carboxamide, Induces Type II Myeloid Cells That Modulate Central Nervous System Autoimmunity.
Evaluation of a multiparametric immunofluorescence assay for standardization of neuromyelitis optica serology.
Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells.
About Tysabri
Evaluation of the immunosuppressive effects of cyclophosphamide in patients with multiple sclerosis.

Pages